Qure.ai has two main products in the fight against TBI and lung disease – qER and qXR. The qXR tool delivers automated chest X-ray interpretation. The technology accurately detects abnormal chest X-ray findings and can be used to distinguish between normal and abnormal X-ray findings, to assist in pre-reading or as a radiology audit tool.
The qER tool (for TBI and stroke detection) can detect intracranial hemorrhage, subdural bleeding, midline shift, and mass effect (for tumor detection) to quickly and accurately analyze head CT scans. He has 32 collective peer review journals and conference papers under his belt, including a review in The Lancet.
Qure.ai reads and interprets medical images such as X-rays, CT and ultrasound in less than a minute. Its AI solutions are FDA-approved, CE-certified and evaluated. World Health Organization.
Prashant Warrier, CEO and founder of Qure.ai, said, “In the last two years, we have achieved 3 FDA clearances for 12 different capabilities and CE certifications in all of our products and increased revenue 10-15 times. We are present in 50 countries touching 4 million lives annually. We have about 100 products and we plan to expand our footprint organically and inorganically, ”he said.
Amit Kakar, Senior Partner, Head, Novo Holdings Equity Asia, said: Something that made Qure.ai very attractive to us in terms of investment, ”he said.
